Sarepta Crashes To Nine-Year Low After A Second Gene Therapy Patient Dies

Sarepta Crashes To Nine-Year Low After A Second Gene Therapy Patient Dies · Investor's Business Daily

In This Article:

Sarepta stock plummeted Monday after the company said a second patient died following treatment with its gene therapy, Elevidys.